Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin

by Stefan Willmann, Matthias Frei, Gabriele Sutter, Katrin Coboeken, Thomas Wendl, Thomas Eissing, Jörg Lippert, Heino Stass
Published 2019-09-01

Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring

by Sonja E. Zapke, Stefan Willmann, Scott-Oliver Grebe, Kristin Menke, Petra A. Thürmann, Petra A. Thürmann, Sven Schmiedl, Sven Schmiedl
Published 2021-05-01

Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

by Stefan Willmann, Kirstin Thelen, Dagmar Kubitza, Anthonie W. A. Lensing, Matthias Frede, Katrin Coboeken, Jan Stampfuss, Rolf Burghaus, Wolfgang Mück, Jörg Lippert
Published 2018-12-01

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

by Alexander Solms, Matthias Frede, Scott D. Berkowitz, Anne Hermanowski‐Vosatka, Dagmar Kubitza, Wolfgang Mueck, Theodore E. Spiro, Stefan Willmann, Xiaoyu Yan, Liping Zhang, Dirk Garmann
Published 2019-11-01

Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome

by Liping Zhang, Xiaoyu Yan, Partha Nandy, Stefan Willmann, Keith A. A. Fox, Scott D. Berkowitz, Amarnath Sharma, Anne Hermanowski-Vosatka, Stephan Schmidt, Jeffrey I. Weitz, Dirk Garmann, Gary Peters
Published 2019-07-01

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study

by Dagmar Kubitza, Stefan Willmann, Michael Becka, Kirstin Thelen, Guy Young, Leonardo R. Brandão, Paul Monagle, Christoph Male, Anthony Chan, Gili Kennet, Ida Martinelli, Paola Saracco, Anthonie W. A. Lensing
Published 2018-12-01

PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients

by Stefan Willmann, Eleonora Marostica, Nelleke Snelder, Alexander Solms, Markus Jensen, Maximilian Lobmeyer, Anthonie W. A. Lensing, Claudette Bethune, Erin Morgan, Rosie Z. Yu, Yanfeng Wang, Shiangtung W. Jung, Richard Geary, Sanjay Bhanot
Published 2021-08-01